Business Context and Reporting Period
Company: Aytu BioScience, Inc. (trading as AYTU on NASDAQ)
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2020
Event: Entry into a Material Definitive Agreement for an upsized firm commitment offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 4,166,667 shares of Common Stock.
- Offering Price: $6.00 per share to the public.
- Over-Allotment Option: 30-day option to purchase up to 625,000 additional shares.
- Expected Net Proceeds: Approximately $22.7 million (after underwriting discounts, commissions, and estimated expenses).
- Use of Proceeds: Working capital and general corporate purposes.
- Underwriter Compensation:
- Underwriting discount: 7.5% of gross proceeds.
- Management fee: 1% of aggregate gross proceeds.
- Warrants: Issuance of warrants exercisable for 6.5% of shares sold.
- Expense reimbursement: Up to $40,000 non-accountable allowance, up to $100,000 legal fees, and $12,900 clearing expenses.
- Warrant Terms: Exercise price of $7.50 (125% of offering price); 5-year term; immediately exercisable.
Material Changes and Outlook
This filing represents a significant capital raise event rather than a periodic financial performance report. Consequently, the document does not contain revenue, profit, cash flow, or margin data for a specific reporting period, nor does it provide comparative financial metrics against prior periods.
Outlook and Management Commentary: The Company intends to utilize the net proceeds to fund working capital and general corporate needs. The offering is expected to close on December 15, 2020, subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected December 15, 2020) and confirm if the over-allotment option was exercised.
- Confirm the actual net proceeds received versus the estimated $22.7 million.
- Review the Company's subsequent filings (e.g., 10-Q or 10-K) to assess the impact of this capital raise on liquidity and cash position.
- Monitor the dilution impact from the issuance of 4,166,667 shares plus potential warrant exercises.
- Check for any updates on the specific allocation of proceeds to working capital versus other corporate purposes.